Disclosed herein are polynucleic acid molecules, pharmaceutical compositions, and methods for treating Facioscapulohumeral muscular dystrophy.

The present invention relates to the treatment of muscular diseases.

A composition for use in a method for the treatment of an amino acid deficiency to a non-mammalian monogastric animal, such as a poultry animal, a fish or a crustacean is described, wherein said composition comprises (i) a mixture of active components comprising or, alternatively, consisting of at least one amino acid or an analogue, (ii) a lipid matrix embedding said (i) mixture of active components and, optionally, (iii) at least one acceptable pharmaceutical or food grade additive and/or excipient. Furthermore, a feed or feed additive for a non-mammalian monogastric animal, such as poultry species and/or aquatic species comprising the composition is also described.

To provide a muscle tissue-regenerating agent containing a fibroin protein.

A muscle tissue-regenerating agent containing a modified fibroin protein.

To provide a muscle tissue-regenerating agent containing a fibroin protein.

A muscle tissue-regenerating agent containing a modified fibroin protein.

The present invention relates to compounds having a lipid affinity of less than 15% by weight of the compound (such as a log P of −0.75 or less) for use in targeting mitochondria to reduce, inhibit or prevent the formation of mitochondrial reactive oxygen species and for use in treating or preventing a pathological condition associated with increased levels of mitochondrial reactive oxygen species, and for non-therapeutic uses, such as enhancing sports performance and reducing, inhibiting or preventing the formation of mitochondrial reactive oxygen species during exercise, resulting in maintenance of muscle strength and/or a reduction in muscle fatigue, and associated methods. The present invention also relates to extracts and compositions comprising compounds having a lipid affinity of less than 15% (such as a log P of −0.75 or less) for the same uses.

The present invention relates to compounds having a lipid affinity of less than 15% by weight of the compound (such as a log P of −0.75 or less) for use in targeting mitochondria to reduce, inhibit or prevent the formation of mitochondrial reactive oxygen species and for use in treating or preventing a pathological condition associated with increased levels of mitochondrial reactive oxygen species, and for non-therapeutic uses, such as enhancing sports performance and reducing, inhibiting or preventing the formation of mitochondrial reactive oxygen species during exercise, resulting in maintenance of muscle strength and/or a reduction in muscle fatigue, and associated methods. The present invention also relates to extracts and compositions comprising compounds having a lipid affinity of less than 15% (such as a log P of −0.75 or less) for the same uses.

A method and composition for increasing muscle protein synthesis in mammals is disclosed. In one embodiment, the mammals are administered a protein building composition comprising at an amino acid component including L-carnitine and a nitrogenous organic acid including creatine. In a particular embodiment, the creatine is in a solution with L-carnitine. The ratio of L-carnitine to creatine can be from about 10:1 to about 1:1. The protein building z composition can be administered in a monolithic enteric capsule.

A method and composition for increasing muscle protein synthesis in mammals is disclosed. In one embodiment, the mammals are administered a protein building composition comprising at an amino acid component including L-carnitine and a nitrogenous organic acid including creatine. In a particular embodiment, the creatine is in a solution with L-carnitine. The ratio of L-carnitine to creatine can be from about 10:1 to about 1:1. The protein building z composition can be administered in a monolithic enteric capsule.

A method and composition for increasing muscle protein synthesis in mammals is disclosed. In one embodiment, the mammals are administered a protein building composition comprising at an amino acid derivative including L-carnitine and a nitrogenous organic acid including creatine. In a particular embodiment, the creatine is in an acid resistant capsule delivery form. The ratio of L-carnitine to creatine can be from about 10:1 to about 1:1. The protein building composition can be administered in a monolithic enteric capsule.